Cork M, Tha?i D, Eichenfield L, Arkwright P, Chen Z, Kamal M, O’Malley J, Bansal A. Dupilumab Provides Acceptable Long-Term Safety and Efficacy in Children Aged ≥ 6 to < 12 Years with Uncontrolled, Severe Atopic Dermatitis: Results From Patients Who Participated in an Open-Label Phase 2a Study and then in a Subsequent Phase 3 Open-Label Extension Study. J of Skin [Internet]. 2020Oct.27 [cited 2024Jul.3];4(6):s104. Available from: https://jofskin.org/index.php/skin/article/view/1100